Lido Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Lido Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.8K	Hold	15,554	–	–	﹤0.01%	1913
2025 Q4	$34.5K	Hold	15,554	–	–	﹤0.01%	1896
2025 Q3	$34.5K	Hold	15,554	–	–	﹤0.01%	1805
2025 Q2	$23K	Hold	15,554	–	–	﹤0.01%	1633
2025 Q1	$39.8K	Hold	15,554	–	–	﹤0.01%	1481
2024 Q4	$29.2K	Hold	15,554	–	–	﹤0.01%	1476
2024 Q3	$15.9K	Hold	15,554	–	–	﹤0.01%	1450
2024 Q2	$18.2K	Hold	15,554	–	–	﹤0.01%	1400
2024 Q1	$19.6K	Hold	15,554	–	–	﹤0.01%	1370
2023 Q4	$27.7K	Sell	15,554 -300	-2%	-$467	﹤0.01%	1329
2023 Q3	$26.3K	Buy	15,854 +300	+2%	+$538	﹤0.01%	1189
2023 Q2	$31.1K	Hold	15,554	–	–	﹤0.01%	1193
2023 Q1	$32.7K	Buy	+15,554	New	+$27.3K	﹤0.01%	1129
2019 Q4	–	Sell	-1,600	Closed	-$3K	–	671
2019 Q3	$3K	Sell	1,600 -114	-7%	-$340	﹤0.01%	574
2019 Q2	$8K	Buy	+1,714	New	+$7.24K	﹤0.01%	536

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Lido Advisors's PLX Position: Q1 2026 in Review

Lido Advisors held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 15,554 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Lido Advisors first reported a position in PLX in Q2 2019 and has held it in 15 quarters since. The position peaked at $39.8K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Lido Advisors held 15,554 shares of Protalix BioTherapeutics worth $33.8K as of Q1 2026.
Lido Advisors left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1913 holding.
Lido Advisors first reported a position in Protalix BioTherapeutics in Q2 2019 and has held it in 15 quarters since.
Lido Advisors's Protalix BioTherapeutics position peaked at $39.8K in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.